Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Completed · Phase 2

Conditions studied: Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis

In brief

The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.

Key facts

Study ID

NCT00447330

Run by

Duke University

People needed

60

Starts

2007-02-01

Expected to finish

2014-07-01

Last updated by the study team

2015-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Duke University Medical Center — Durham, North Carolina, United States
• University of Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.